about
Prevalence and risk factors for chronic co-infection in pulmonary Mycobacterium avium complex disease.The influence of environmental exposure on the response to antimicrobial treatment in pulmonary Mycobacterial avium complex diseaseRapidly progressive sarcomatoid malignant mesothelioma of the pleura mimicking pulmonary empyemaConcomitant T790M mutation and small-cell lung cancer transformation after acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor.Giant mature teratoma in the mediastinum presenting with rapid growth.Small cell lung cancer transformation during immunotherapy with nivolumab: A case report.Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.Patient with lung adenocarcinoma manifesting as an unusual migratory pulmonary infiltration.Association between polyclonal and mixed mycobacterial Mycobacterium avium complex infection and environmental exposure.Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab.Acute onset of ulcerative colitis during chemoradiotherapy for anaplastic lymphoma kinase-positive lung adenocarcinoma.Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.Association between Mycobacterium avium complex lung disease and serum vitamin D status, antimicrobial peptide levels, and bone mineral densityNivolumab-induced severe acute kidney injury with a long latent phase in a patient with non-small-cell lung cancer: A case reportSeptic pulmonary embolism complicated by pyogenic spondylitis and psoas abscesses in a patient with methicillin-sensitive bacteraemiaA case of pulmonary lymphoproliferative disorder presenting rapidly progressive respiratory failureEnvironmental risk factors for pulmonary Mycobacterium avium-intracellulare complex diseaseCase Report: Disseminated Mycobacterium kansasii Disease in a Patient with Anti-Interferon-Gamma AntibodyDevelopment of Mycobacterium avium Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint InhibitorsTherapy-related acute myeloid leukemia after chemotherapy in extensive disease-small cell lung cancerEmerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapyRetreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibodyRetreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 AntibodiesIncidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint InhibitorsQuantitative SARS-CoV-2 antibody screening of healthcare workers in the southern part of Kyoto city during the COVID-19 peri-pandemic period
P50
Q34419659-BB583C05-E6EF-40EA-84A8-44B461389331Q34669152-4DDB727A-D4BE-4395-BCB9-55B9F04DF16FQ36188401-46E1E974-1A76-4C41-9672-6D8F64B8738FQ37515387-BEB31A15-49E3-42E7-A4CB-22F96D2B6889Q37532520-F24B0E0F-14E3-458E-8FD0-327E8CD87418Q37733355-2BDB2B63-BA24-4F98-90BC-51AE765AFA80Q40611407-2F5F1592-C3D2-4A1D-8146-4BD3992BE9DBQ41824573-9E10A4BD-AB5A-4847-B6C0-0B504AF92696Q44619479-3551216C-21B0-4A9D-972D-D61DDB5F9518Q47349715-94B28C2D-D469-43F7-8E7E-C8AC9C2F1B9CQ47660470-308F6228-AD00-489A-9CEA-1B94BA58CF19Q52718053-BE4F62F2-1A3D-4938-ACF6-F8FBF9ACE80FQ58704311-29C50890-BCD1-4AF5-B476-9290C42FDCA5Q59130130-B83760DD-2E8E-464A-8D72-BEB42B9B280BQ59334851-FABBA04F-6732-484E-9204-04EE2FD4D661Q64086923-9257D7AC-52C1-4A58-AA9C-CDC88F2D1F49Q83584153-3C9272EC-A2FE-4D32-AE7F-3A4C3EF62604Q90250459-E5E55CB2-ECBB-4A92-9D9C-40A0D0334C75Q90451724-7F2FC424-20F5-40FE-8BC2-BC49D0414380Q91101978-1EC2C967-8981-4448-B1FF-3348A09C4CA4Q91146297-736F24AD-7806-4576-9641-2B5810E51C9AQ91181956-625A06B2-43FA-4F6A-9CC2-025620F4092FQ91527207-15F11EBD-DF53-4B20-8F30-0FFEA30BBABCQ94547633-901BAD56-2D0E-4E26-80C3-789E37F2A041Q95602913-F37A5953-DE35-48D0-B41B-882B2D6CD1DA
P50
description
researcher ORCID ID = 0000-0002-6902-9085
@en
wetenschapper
@nl
name
Kohei Fujita
@ast
Kohei Fujita
@en
Kohei Fujita
@es
Kohei Fujita
@nl
type
label
Kohei Fujita
@ast
Kohei Fujita
@en
Kohei Fujita
@es
Kohei Fujita
@nl
prefLabel
Kohei Fujita
@ast
Kohei Fujita
@en
Kohei Fujita
@es
Kohei Fujita
@nl
P1153
55628535972
P31
P496
0000-0002-6902-9085